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Abstract
Minisatellites, also called variable number of tandem repeats (VNTRs), are a class
of repetitive elements that may affect gene expression at multiple levels and have
been correlated to disease. Their identification and role as expression quantitative
trait loci (eQTL) have been limited by their absence in comparative genomic
hybridization and single nucleotide polymorphisms arrays. By taking advantage of
cap analysis of gene expression (CAGE), we describe a new example of a
minisatellite hosting a transcription start site (TSS) which expression is dependent
on the repeat number. It is located in the third intron of the gene nitrogen
permease regulator like protein 3 (NPRL3). NPRL3 is a component of the GAP
activity toward rags 1 protein complex that inhibits mammalian target of
rapamycin complex 1 (mTORC1) activity and it is found mutated in familial focal
cortical dysplasia and familial focal epilepsy. CAGE tags represent an alternative
TSS identifying TAGNPRL3 messenger RNAs (mRNAs). TAGNPRL3 is expressed in
red blood cells both at mRNA and protein levels, it interacts with its protein
partner NPRL2 and its overexpression inhibits cell proliferation. This study
provides an example of a minisatellite that is both a TSS and an eQTL as well as
identifies a new VNTR that may modify mTORC1 activity.
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1 | INTRODUCTION
The mammalian genome encodes the instructions to specify development
from the zygote to the generation of full sets of organs necessary to
become an adult, interact with the environment and reproduce
(Abugessaisa et al., 2017; FANTOM Consortium and the RIKEN PMI
and CLST DGT et al., 2014). The fine regulation of gene expression is
extremely complex and requires several players for its correct tuning in
time and space. Slight alterations could have dramatic cascade effects
leading to loss of homeostasis and disease (Chen et al., 2008; Cookson,
Liang, Abecasis, Moffatt, & Lathrop, 2009; Emilsson et al., 2008).
In these conditions, specific sets of transcription factors are induced
or repressed. These factors provide proximal and distal regulatory
inputs that are integrated at transcription start sites (TSSs) to control
the expression of target genes. Most genes have more than one TSS,
and the regulatory inputs that determine TSS choice and activity are
diverse and complex (Abugessaisa et al., 2017; FANTOM Consortium
and the RIKEN PMI and CLST DGT et al., 2014). A comprehensive
overview of TSSs and promoters’ usage across the human body has
been recently assembled by taking advantage of cap analysis of gene
expression (CAGE; Abugessaisa et al., 2017; FANTOM Consortium and
the RIKEN PMI and CLST DGT et al., 2014), a technology based on the
generation of short sequence tags from the 5′ end of full‐length
complementary DNAs (cDNAs) followed by high‐throughput sequen-
cing. When mapped to a reference genome, CAGE tags survey TSSs
activity of specific promoters and measure expression levels on a
massive scale (Carninci et al., 2006; Suzuki et al., 2009).
Genome‐wide association studies have identified hundreds of genetic
variants that affects human phenotypes or susceptibility to diseases. In
this context, a long‐standing challenge is the unraveling of the chain of
molecular events linking genetic variation to gene expression. To this
purpose, a large effort has been devoted to identify expression
quantitative trait loci (eQTL) correlating genetic polymorphisms to
expression profiles (Jansen & Nap, 2001). Although eQTL identification
has helped to unveil the molecular basis of some complex disorders,
genomic analyses have been mainly focused on single nucleotide
polymorphisms (SNPs). More recently, by taking advantage of the 1000
Genome Project, gene expression differences have been correlated to
selected structural variants (SVs; 1000 Genomes Project Consortium
et al., 2015). A substantial portion of SVs involves repetitive elements
(REs), sequences that occur multiple times in the genome. These present
a large variety of DNA elements of diverse structure and origin. REs can
be grouped into two classes: tandem repeats (TRs) are small nucleotide
stretches repeated in a head‐to‐tail orientation, while transposable
elements are DNA sequences with the ability to move from one place of
the genome to another. They represent almost 50% of the human
genome (Babatz & Burns, 2013).
Minisatellites, also called variable number of tandem repeats
(VNTRs), are a class of RE that have a unit length of 10–60bp with a
conserved core sequence of 10–15 bp, spanning 0.1–15 kb. VNTRs are
frequently found in functional genic regions (such as coding sequence,
promoter, untranslated region [UTR]) and may affect gene transcription,
messenger RNA (mRNA) splicing, posttranscriptional modification or
translational efficiency (Brookes, 2013). In selected cases, a causative link
between their copy number and gene expression has been proved
(Manca et al., 2018; van Dyck et al., 2005; Warburton, Breen, Bubb, &
Quinn, 2016). Importantly, VNTRs have been correlated to human
diseases (Brummett et al., 2007; Faraone, Doyle, Mick, & Biederman,
2001; Kennedy, Weed, Forget, & Morrow, 1994; Ogilvie et al., 1996).
Unfortunately, our understanding of their role as eQTLs has been
limited by their absence in comparative genomic hybridization (CGH)
and SNPs arrays.
The nitrogen permease regulator‐like 3 (NPRL3) gene is adjacent to
the α globin cluster on chromosome 16p13.3 and gives rise to five NPRL3
mRNAs isoforms differing in their 5′‐UTR regions including the
translational starting codon (Vyas, Vickers, Picketts, & Higgs, 1995).
NPRL3 expression is ubiquitous and high in human and mouse erythroid
cells (Kowalczyk et al., 2012a; Lower et al., 2009). NPRL3 protein
dimerizes with its homologous NPRL2 and together with DEPDC5 they
form GAP activity toward rags 1 (GATOR1), a protein complex
responsible of mammalian target of rapamycin complex 1 (mTORC1)
inhibition. Recently, NPRL3 gene mutations have been found in patients
with familial focal cortical dysplasia (FCD) and familial focal epilepsy,
leading to pathological mTOR activation (Sim et al., 2015).
Our laboratories have been interested in the etiology and
molecular diagnosis of Parkinson’s disease (PD), a slowly progres-
sive degenerative disorder of the central nervous system. No
pharmacological treatment is currently available to slow or arrest
the neurodegenerative process. Furthermore, accurate early
diagnosis suffers from the lack of reliable biomarkers. In the
quest of a gene expression signature for PD, we have previously
shown that gene expression profiling of peripheral blood
samples discriminates PD patients from healthy controls identify-
ing differentially expressed genes by the use of the Affymetrix
platform (Calligaris et al., 2015).
In a follow‐up study, we have taken advantage of CAGE applied
to tiny amounts of RNAs (Grison et al., 2014; Pascarella et al., 2014;
Plessy et al., 2010, 2012), to describe TSS usage in the peripheral
blood of 20 drug‐naïve de novo PD patients and 20 healthy age and
sex matched controls (HC), a subset of those previously analysed
(Calligaris et al., 2015).
While a complete analysis of differential gene expression is not
the topic of this study and it will be described elsewhere, here we
report the identification of a new alternative TSS for NPRL3
(TAGNPRL3) that lies within a 29 nt long minisatellite. High
expression is associated to the presence of 13‐repeats allele while
the 16‐repeats allele is the most common. Although neither
expression or allelic frequency is related to PD, TAGNPRL3 from
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16/13 genotypes is highly expressed in red blood cells (RBCs). It
encodes for a protein lacking the N‐terminal part but able to bind
NPRL2 and inhibit cell proliferation as its full‐length isoform.
This study provides a novel example of a TSS located in a
minisatellite, which usage depends on the number of TRs increasing
the repertory of sequence architectures for cis‐acting eQTLs.
2 | MATERIAL AND METHODS
2.1 | Blood collection and RNA purification
The study was approved by the local institutional Ethical Committee
at the Movement Disorders Center of the Neurologic Clinic of
Trieste (Italy). Study participants gave written informed consent. We
enrolled 20 patients with a first clinical diagnosis of PD, according
to the UK Parkinson’s Disease Society Brain Bank criteria. Twenty
healthy age‐ and ethnicity‐matched control subjects (HC) traveling
with the patients were also included in the study.
Blood was collected from study subjects after a fasting period.
Samples were harvested directly and sequentially into eight PAXgene
Blood RNA tubes (PreAnalytiX, Hombrechtikon, CH) via a 21G butterfly
needle and then frozen and kept at −80°C. Total RNA was purified using
PAXgene™ Blood RNAKit (PreAnalytiX GmbH, Qiagen, Hilden, Germany)
and DNase I treatment was performed by “on‐column” treatment as
recommended by manufacturer’s instructions plus a second treatment
subsequent to elution. RNA was then purified using RNase column
(Qiagen, Hilden, Germany) and quantified by Nanodrop ND‐100
Spectrophotometer (NanoDrop Technologies, Wilmington, DE). RNA
integrity was determined with 2100 Bioanalyzer (Agilent Technologies,
Palo Alto, CA) and exclusively samples with RNA integrity number≥8
were included in the subsequent investigations.
2.2 | Cap analysis of gene expression
The CAGE libraries were prepared and analyzed as previously described
(Hasegawa, Daub, Carninci, Hayashizaki, & Lassmann, 2014; Takahashi,
Kato, Murata, & Carninci, 2012). First, cDNA was reverse‐transcribed by
the reverse transcriptase using a random primer including an Eco P15I
sequence. First‐strand cDNA reaction was then cleaned up and
Cap‐trapping was performed. Chemical oxidation with NaIO4 was used
to open the RNA diol groups. The derived oxidized dialdehyde was
incubated with a long arm biotin hydrazide, resulting in biotinylation of
the cap‐site and the 3′ ends of RNAs. Before capturing the biotinylated
cap, samples were treated with RNase I to cleave single stranded RNA
(ssRNA) regions followed by a short incubation at 65°C. The cDNAs
including the biotinylated cap site were finally captured with streptavidin‐
coated magnetic beads.
By the single‐strand linker ligation method, a primer sequence for
second strand cDNA synthesis was added. The second strand cDNA
synthesis was then initiated by a biotin modified primer and carried out
with a thermostable DNA polymerase. cDNA was then treated with
Antarctic phosphatase and cleaved by Eco P15I, a Type III restriction
enzyme that cleaves 27 nt downstream of the enzyme recognition site.
After cleavage, the 3′ linker, ending with two NN protruding nucleotides,
was ligated at the Eco P15I cleavage site providing a priming site for the
subsequent polymerase chain reaction (PCR) amplification carried out
with Phusion High‐Fidelity DNA Polymerase (Thermo Scientific).
2.3 | Rapid amplification of cDNA ends (RACE)
RACE technique allows the amplification of full‐length 5′ and 3′ ends
of cDNA starting from a known partial sequence obtained, for
example, from library screening such as CAGE.
RACE was performed using the GeneRacer cDNA Amplification
Kit (Invitrogen).
One microgram of total RNA has been retrotranscribed into
cDNA modified with the GeneRacer 5′ and 3′ adaptors following the
manufacturer’s protocol, using poly‐T primer in the 20 µl reverse
transcription reaction.
All RACE reactions were performed by nested PCR. For the
first amplification, 1 μl cDNA obtained from the retrotranscription
reaction was used as a template together with GeneRacer™ 5′ Primer
or the GeneRacer™ 3′ Primer, when performing 5′ or 3′ RACE
reactions, respectively, and gene‐specific primers: REV_first_5RACE
(CCCAGAGCATGCTGTAGCAGTGTT) for 5′RACE and FW_3RACE
(GAGTGTGTGATCCTGTTTCTCAGCGTG) for 3′RACE.
PCR was performed with Platinum Taq High Fidelity (Invitrogen)
under the following conditions: 94°C for 2min, followed by five
cycles at 94°C for 30 s, 72°C for 1min; five cycles at 94°C for 30 s,
70°C for 1min, 25 cycles at 94°C for 30 s, 68°C for 30 s, 68°C for
1min, and a final extension at 68°C for 10min.
One microliter of this PCR product was used as template for the
nested PCR together with GeneRacer™ 5′ Nested Primer or the
GeneRacer™ 3′ Nested Primer, when performing 5′ or 3′ reactions,
respectively, and a second nested gene‐specific primer: REV_neste-
d_5RACE (ATAACATCTGAAAACCAGACAAGAAACA) for 5′‐RACE
and FW_3RACE (the same of the first reaction) for 3′‐RACE.
Nested PCR was performed under the following conditions: 94°C
for 2min, followed by 40 cycles at 94°C for 30 s, 65°C for 30 s, 68°C
for 2min, and a final extension at 68°C for 10min. PCR products
were resolved on 1% agarose gel. The amplicons were cloned in
pGEM‐T Easy vector (Promega) and sequenced at the Eurofins MWG
Operon Inc. facility.
2.4 | Identification of minisatellite polymorphism
The validation set of PD and HC samples was obtained from the PD
DNA Bank at the Centro Studi Parkinson (Milan, Italy) and additional
HC from the Associazione Donatori di Sangue (Trieste, Italy).
The independent set of PD and HC samples was obtained from
“Clinica Neurologica di Trieste” and “Telethon Biobank” for PD, and
from “Associazione Donatori Sangue Trieste” for HC.
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Genomic DNA has been extracted from blood samples taking
advantage of QIAamp DNA Blood Mini Kit (Qiagen) following the
manufacturer’s protocol.
PCRs were performed in 96‐well plates, on a total of 20 ng/5 µl
of human genomic DNA per well, by using ExTaq TaKaRa on a
total of 50 µl reaction volume, as specified by the manufacturer.
Primers are VNTR_FW (GCAGAAGTGCCACCATTAAGCA),
VNTR_REV (AAACCCCATGGTAAGCGTTGA) and they were
used at a final concentration of 200 nM. The two primers
were designed to map externally to the repeated region to
obtain the amplification of the entire minisatellite. The cycling
conditions were: 94°C for 3min, followed by 35 cycles at 94°C for
30 s, 62.4°C for 30 s, 72°C for 1min, and a final extension at 72°C for
5min. Reaction products were visualized on a 1.3% agarose gel.
2.5 | Reverse transcription PCR (RT‐PCR) and
real‐time TaqMan PCR
To validate the full‐length TAGNPRL3 transcript, 1 µg of total RNA
was reverse‐transcribed in a final volume of 20 μl using Superscript
III Reverse Transcriptase (Invitrogen), 25 ng random hexamers and
2.5 μM oligo(dT) 20 primers according to the manufacturer’s
recommendations.
PCR mix was prepared by adding 1 μl of the so prepared cDNA to
5 units of TaKaRa Ex Taq, 10× Ex Taq Buffer, dNTP Mixture (200 µM
final concentration each) (TaKaRa), 200 nM of primer FW_3RACE
(see Table 2), 200 nM of primer REV (CCTTTCCAAACCTGCGCACC),
and water to a final volume of 50 μl.
The FW_3RACE is the same forward primer used to amplify the
full‐length transcript in 3′RACE assay, while the REV primer was
designed in the 3′‐UTR region of TAGNPRL3. The primers used to
amplify NPRL3 isoform 1 are NPRL3_FW (CCCCACGGCGGG
ATGCGGGA) and NPRL3_REV (TCGCCCGTGTTGCTGGCAGCGT).
The PCR protocol is the following: 95°C for 5 min, followed by
40 cycles at 95°C for 15 s, 60°C for 1min, 72°C for 1 min, and a final
extension at 72°C for 5min. PCR products were resolved on 1%
agarose gel.
Real‐time PCR was performed in the presence of 1 μl of
cDNA template, TaqMan gene expression master mix, commercially
available TaqMan gene expression assay for PGK1
(Hs99999906_m1), 250 nM specific primer mix, 150 nM specific
TaqMan MGB probe (6‐carboxyfluorescein dye‐labelled) and run on
an iCycler IQ (Bio‐Rad) in a 20 μl reaction volume according to the
manufacturer’s instructions. Each sample has three technical
replicates. PGK1 has been used as a reference gene for this study
because it was among the most reliable reference genes for
peripheral blood gene expression analyses (Calligaris et al., 2015).
NPRL3_FW and NPRL3_REV primers have been used together
with the following specific probe on Nprl3 isoform 1: AGCCAGGA
GCACCCGGCGTCC.
The specific primers and probes designed on TAGNPRL3 are
TAGNPRL3_FW (GTGATCCTGTTTCTTGTCTGGT), TAGNPRL3_REV
(CAGAGCATGCTGTAGCAGTGT), and the probe GTTATTCTGGC
AACAATTTTGGCA.
Thermal cycler conditions were as follows: 95°C for 10min,
followed by 40 cycles of amplification at 95°C for 15 s and 60°C
for 1min.
Standard curves of cDNA ranging from 120 to 0.2 ng
were used to verify that the 50 ng dilution tested was within
the linear range of reaction. Primer efficiency and multiplexing
efficacy was verified by linear regression to the standard curve
with a slope near −3.32 representing acceptable amplification
efficiency.
The amplified products were separated on a 2% agarose gel.
Results were normalized to PGK1 and the initial amount of the
template of each sample was determined as relative expression
versus a pool of healthy control samples used as calibrator. The
relative expression of each sample was calculated by the formula
−ΔΔ2 Ct (User Bulletin 2 of the ABI Prism 7700 Sequence Detection
System).
2.6 | RNA and protein preparation from blood
fractions
Blood was collected into ethylenediaminetetraacetic acid (EDTA)
tubes and the plasma, the RBCs and the peripheral blood mono-
nuclear cells (PBMCs) have been separated starting from the whole
blood samples by using Ficoll Histopaque gradient following the
manufacturer’s protocol (Sigma‐Aldrich).
To extract total RNA from the blood fractions each sample was
added with a proper amount of TRIzol reagent (Invitrogen) followed
by manufacturer’s protocol.
A fraction of the total RNA sample was treated with DNase I
(Ambion) at 37°C for 1 hr, and the sample was then purified on
RNAeasy Mini Kit columns (Qiagen). The final quality of RNA sample
was tested on the Agilent 2100 bioanalyzer using the Eukaryote
Total RNA Nano assay.
The PBMC protein lysate has been prepared adding a proper
amount of 2× sodium dodecyl sulfate (SDS) sample buffer (100mM
Tris‐HCl (pH 6.8), 4% (w/v) SDS, 0.2% (w/v) bromophenol blue, 20%
(v/v) glycerol, 200mM β‐mercaptoethanol). The protein lysates from
whole blood, plasma, and RBCs have been prepared according to
Lin et al. (2012) (“Whole blood sample preparation” chapter)
followed by an albumin depletion using trichloroacetic acid/acetone
(Chen et al., 2005).
The obtained precipitates were diluted in a proper amount of 2×
SDS sample buffer.
2.7 | Expression plasmids
NPRL3: pcDNA3 vector containing the full‐length DNA sequence of
human NPRL3 isoform 1 and pcDNA3 vector containing coding DNA
sequence of human NPRL3 isoform 2 were kindly provided by Licio
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Collavin’s laboratory (Consorzio Interuniversitario per le Biotecno-
logie, Trieste).
TAGNPRL3: the full‐length DNA sequence of TAGNPRL3 was
amplified from whole blood cDNA modified with the GeneRacer 5′
and 3′ adaptors via PCR with the GeneRacer™ 5′ Primer (see Table 2)
and a gene specific reverse primer: TTTTGCTTGGCCTGG
CTTTTATCTTGAA.
The pGEM T‐easy‐TAGNPRL3 plasmid was generated by subclon-
ing the cDNA sequence into the EcoRI cloning site of the pGEM T‐
easy cloning vector from Promega for sequencing. This cassette was
finally cloned into the pcDNA3.1 (−) expression vector using the
same restriction enzymes.
NPRL2_Myc: pcDNA3.1‐vector containing the coding region of
human NPRL2 amplified from whole blood cDNA. The Myc tag was
fused to the C‐terminus of the protein.
2.8 | Cell culture, transfections, and
immunoblotting
HEK 293T (human embryonic kidney) cells were grown in DMEM
(Gibco) supplemented with 10% fetal bovine serum (Sigma‐Aldrich),
100 U/ml penicillin and 100 μm/ml streptomycin (Sigma‐Aldrich) at
37°C in a humidified CO2 incubator. HEK cells were transfected with
FuGENE HD Transfection Reagent (Promega) following manufac-
turer instructions. After 48 hr from transfection, cells were either
collected with 2× SDS sample buffer or analysed via immunofluor-
escence.
All the protein lysates have been boiled 5min at 95°C and
analysed by western blot.
For western blot, samples were resolved on SDS/polyacryla-
mide gel electrophoresis, and proteins were transferred to
nitrocellulose membrane (Amersham, GE Healthcare). Membrane
was blocked with 5% nonfat milk in Tris buffer saline solution
(TBST), then incubated overnight at 4°C with the following
primary antibodies: anti‐NPRL3 (1:500; Cat #ab121346; RRI-
D:AB_11129281; Abcam), anti‐β Actin (1:5,000; Cat #A5441;
RRID:AB_476744; Sigma‐Aldrich).
Proteins were detected by horseradish peroxidase‐conjugated
secondary antibodies (DakoCytomation, Glostrup, Denmark) and ECL
Western Blotting Detection Reagents (GE Healthcare).
2.9 | Small interfering RNA (siRNA) experiment
By taking advantage of siTran 2.0 siRNA transfection reagent
(Cat. no.: TT320001; Origene), SH‐SY5Y cells were transfected with
10 nM siRNA for human NPRL3 (Human) (Cat. no.: SR305374;
Origene) and with a Universal scrambled negative control siRNA.
Fluorescent labeled siRNA has been used to optimize transfection
efficiency (Trilencer‐27 Fluorescent‐labeled transfection control
siRNA duplex; 1 nmol; Cat. no.: SR30002; Origene). Forty‐eight later
samples were harvested for western blot and qRT‐PCR analysis.
2.10 | Immunofluorescence
For immunocytochemistry experiments, cells were fixed in 4%
paraformaldehyde (Sigma‐Aldrich) for 10min, then washed with
phosphate‐buffered saline solution (PBS) two times, treated with
0.1M glycine for 4 min in PBS and permeabilized with 0.1% Triton
X‐100 in PBS for another 4min. After washing with PBS and blocking
with 0.2% bovine serum albumin (BSA), 1% normal goat serum, 0.1%
Triton X‐100 in PBS (blocking solution), cells were incubated with
the indicated antibodies diluted in blocking solution for 90min at
room temperature. After washes in PBS, cells were incubated with
labelled secondary antibodies for 60min. For nuclear staining, cells
were incubated with 1 μg/ml 4′,6‐diamidino‐2‐phenylindole (DAPI)
for 5min. Cells were washed and mounted with antifade fluorescent
mounting medium (Vectashield Hard Set, VectorLabs). All images
were collected using a Leica DM6000 fluorescence microscope.
2.11 | Coimmunoprecipitation
HEK cells were transfected with FuGENE HD Transfection Reagent
(Promega) following manufacturer instructions. After 24 hr from
transfection, cells were harvested and lysed in the following buffer
supplemented with complete EDTA‐free Protease Inhibitor Tablets
(Roche): 150mM NaCl, 50mM Tris‐HCl pH 7.4, 0.5% NP‐40,
1mM EDTA.
After 30min of lysis at 4°C samples were sonicated twice (7 μm
amplitude, 10 s) and then centrifuged 30min, 4°C at maximum speed.
Supernatants were collected and a fraction was saved as input.
Lysates were incubated with 1 µl of Myc‐Tag (9B11) antibody from
Cell Signaling Technology (Cat# 2233S, RRID:AB_10693328).
After 3 hr of incubation, 40 µl of Protein G Sepharose beads
(GE Healthcare) were added to each sample and incubated 1 hr.
After washing, beads were dried and eluted in 2× SDS sample buffer,
boiled 5min at 95°C and analysed by western blot.
2.12 | Bromodeoxyuridine (BrdU) assay
HEK cells were transfected with FuGENE HD Transfection Reagent
(Promega) following manufacturer instructions. As a control, a
pcDNA3.1‐vector expressing green fluorescent protein (GFP) was
used. After 48 hr from transfection, BrdU was added to each plate
at a final concentration of 15 µg/ml for 1 hr.
Cells were then fixed in 4% paraformaldehyde (Sigma‐Aldrich) for
10min, then washed with PBS two times, treated with 0.1M glycine
for 4 min in PBS and permeabilized with cold acetone for 30 s. After
washing with PBS cells are treated with HCl 3 N for 15min to
separate DNA into single strands so the primary antibody can access
the incorporated BrdU. After several washes with PBS cells were
incubated at 37°C with a blocking solution of 1% BSA for 30min,
followed by 37°C incubation with an anti‐BrdU antibody (1:50;
Cat #B2531; RRID:AB_476793; Sigma‐Aldrich) and an anti‐NPRL3
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antibody (1:500; Cat #ab121346; RRID:AB_11129281; Abcam) in
blocking solution for 90min. After washes in PBS, cells were
incubated with labelled secondary antibodies for 60min. For nuclear
staining, cells were incubated with 1 μg/ml DAPI for 5 min. Cells were
washed and mounted with antifade fluorescent mounting medium
(Vectashield Hard Set, VectorLabs). All images were collected using a
Leica DM6000 fluorescence microscope.
The significance of differences between the means in experi-
mental groups and conditions was analyzed using one‐way ANOVA
followed by post hoc Tukey test or Dunnet’s multiple comparison test,
or nonparametric tests (for small data samples) Wilcoxon test, using
Prism (GraphPad Software Inc.). Significance levels indicated in all
figures are as follows: **p < .01, ***p < .001.
3 | RESULTS
3.1 | CAGE analysis of peripheral blood identifies
a highly expressed tag in the intronic region of the
NPRL3 gene
In a follow up of Calligaris et al. (2015), we have taken advantage of
CAGE to map TSSs in the peripheral blood of 20 drug‐naïve de novo
PD patients and 20 age and sex matched healthy controls (HC). On
average for each CAGE library, 7,158,414 tags were sequenced
and 1,799,298 were uniquely mapped to the reference genome
(Table S1). A complete analysis of differential gene expression
between PD and HC will be described elsewhere and it is not the
topic of this study.
In this study, we focus our attention on a CAGE tag (27 nt) that
was found upregulated by more than 50‐fold in six out of 20 (30%)
PD individuals respect to the remaining patients and HC. This highly
expressed tag maps to the third intron of the NPRL3 gene, on the
telomeric region of chromosome 16, with coordinates 173660‐
174239 (genomic assembly hg19). The multimapping nature of this
tag is appreciable on Figure 1, suggesting it represents a repetitive
region. By Genome Browser sequence analysis, this tag maps on
a minisatellite sequence of 29 nucleotides repeated 16 times. The
mapping is on the (−) strand of genomic DNA, in the same direction of
NPRL3 transcription. This minisatellite is present only in this genomic
locus and it is human‐specific. The most common tag sequence is
GAGTGTGTGATCCTGTTTCTCAGCGTG. Table 1 reports the tag
per million (tpm) values of the 40 CAGE samples. Samples presenting
the highest tag levels are PD2 (30.08), PD4 (23.12), PD7 (19.42),
PD11 (46.05), PD13 (50.88), PD18 (45.57), while the average tpm for
the remaining PD are 1.89 and for HC are 1.43.
3.2 | Identification of tag‐containing transcripts
To identify tag‐containing transcripts we took advantage of 3′RACE
applying this technique to the PD sample that presented the highest
amount of tags on the CAGE assay (PD13; Table 1). PD13 RNA was
retrotranscribed into cDNA modified with the GeneRacer 3′ adaptor
F IGURE 1 CAGE tags upregulated in PD samples in the intronic region of NPRL3 (chr16:173660‐174239 on hg19). The UCSC Genome
Browser screenshot shows the intronic region of NPRL3, a minisatellite sequence detected by the Tandem Repeats Finder, and several raw
coverage plots of CAGE tags. The first two coverage plots are an aggregation of all control (red) and patient (blue) samples. The following six
coverage plots shows the patient samples with the highest number of CAGE tags: PD2, PD4, PD7, PD11, PD13, and PD18. CAGE, cap analysis
of gene expression; NPRL3, nitrogen permease regulator like protein 3; PD, Parkinson’s disease
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using poly‐T primer and the first‐step RT‐PCR was carried out using the
GeneRacer 3′ Primer and a forward primer corresponding
to the tag sequence (Figure 2a). Nested RT‐PCR, performed using
the GeneRacer 3′ Nested Primer and the same forward primer, allowed
amplification of a major product (about 2,000 bp; Figure 2e). Subcloning
and sequencing of this fragment revealed a new NPRL3 isoform with the
TSS in the third intron of the NPRL3 gene (Figure 2b).
Together with this major product of amplification, we identified
four NPRL3‐hemoglobin A1 chimeric transcripts that we called
transalpha1–4. The breakpoints of these transcripts involve the
intronic minisatellite sequence (2–4 repeats are transcribed) and the
third exon of hemoglobin 1A (HBA1). Only in one case (transalpha4)
we could observe a more complex transplicing RNA composed of
minisatellite intronic sequences spliced to the subsequent two exons
of NPRL3 interrupted by part of the second and all the third exons of
HBA1 (Figure 3). Unfortunately, we were not able to validate these
chimeric transcripts due to the high abundance of HBA1 mRNA in
blood samples.
We then completed our study of the tag‐containing transcript with a
5′RACE experiment. To this purpose, we took advantage of another high
tag‐expressing PD blood sample (PD11; Table 1). After confirming that
this PD patient expressed the same tag‐containing transcript of PD13
with a 3′RACE experiment (data not shown), the first‐step RT‐PCR for
the 5′RACE was carried out using the GeneRacer 5′ Primer and a
reverse primer located to the fourth exon of the NPRL3 gene. 5′RACE
nested RT‐PCR was performed using the GeneRacer 5′ Nested Primer
and a nested reverse primer spanning the fourth NPRL3 exon and the
transcribed intronic sequence found with 3′RACE (Figure 2c). The 5′
RACE gel run revealed the amplification of a major product (about
200bp) (Figure 2f) that mapped the TSS of this new NPRL3 isoform
(TAGNPRL3) to the minisatellite sequence of NPRL3 third intron
(Figure 2d). Interestingly, TAGNPRL3 TSS sequence is TC+1TTTCT which
strongly resemble a TCT motif (YC+1TYTYY), a key component of an
RNA polymerase II system that is directed toward the expression of
ribosomal protein genes as well as other genes encoding factors involved
in protein synthesis (Parry et al., 2010). Despite the high sequence
homology between the different repeats, the consensus TC+1TTTCT is
present only in the eleventh repeat providing TSS specificity.
To validate the TAGNPRL3 transcript identified with RACE, we
carried out an RT‐PCR experiment with a reverse primer in the 3′‐
UTR region and the same forward primer of the 3′RACE assay
mapping to the CAGE tag sequence (Figure 4a). We thus confirmed
that TAGNPRL3 is the RNA isoform detected as differentially
expressed in the CAGE experiment since PD13 and PD2, high‐
expressing tag samples, showed a higher level of TAGNPRL3
compared with the low‐expressing tag sample HC14 (Figure 4b).
The identity of the amplicon was confirmed by sequencing.
On the contrary, by performing an RT‐PCR with primers specific
for the NPRL3 isoform 1, we showed that its expression is quite
comparable among the three samples (Figure 4c).
TABLE 1 Cap analysis of gene expression upregulated tag in PD:
tpm values for each HC and PD sample, mapping on chr16:173660‐
174239 region (hg19)
Sample tpm
HC1 1.48
HC2 1.19
HC3 2.15
HC4 0.27
HC5 1.84
HC6 1.18
HC7 1.76
HC8 0.90
HC9 0.19
HC10 0.69
HC11 2.94
HC12 1.43
HC13 0.92
HC14 1.84
HC15 3.92
HC16 0.68
HC17 1.30
HC18 0.88
HC19 2.42
HC20 0.62
PD1 0.62
PD2 30.08
PD3 4.16
PD4 23.12
PD5 0.55
PD6 0.15
PD7 19.42
PD8 0.81
PD9 5.21
PD10 2.67
PD11 46.05
PD12 1.78
PD13 50.88
PD14 1.61
PD15 1.89
PD16 0.65
PD17 1.06
PD18 45.57
PD19 3.19
PD20 2.14
Abbreviations: HC, healthy control; PD, Parkinson’s disease; tpm, tag per
million.
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3.3 | TAGNPRL3 expression levels are associated
to the minisatellite genotype
Given the high variability in the number of repeats of minisatellite
sequences, we investigated whether the minisatellite containing
TAGNPRL3 TSS is polymorphic. To this purpose, we designed two
primers that map externally to the repeated region to obtain the
amplification of the entire minisatellite sequence. PCR experiments
on genomic DNA revealed the presence of two amplification
products (Figure S1). By sequencing, we found that these PCR
F IGURE 2 Identification of the tag containing transcripts by 3′ RACE‐PCR analysis and validation by 5′ RACE‐PCR analysis. (a) UCSC
Genome Browser snapshot showing the position of 3′RACE primer. The PCR product run on a 1% agarose gel is shown in (e)). (b) 3′RACE
product sequence blat on UCSC Genome Browser. (c) UCSC Genome Browser snapshot showing the position of 5′RACE primers. The PCR
product run on a 1% agarose gel is shown in (f)). (d) 5′RACE product sequence blat on UCSC Genome Browser. PCR, polymerase chain reaction;
RACE, rapid amplification of cDNA ends
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F IGURE 3 Identification of chimeric products by 3′ RACE‐PCR analysis. (a) Schematic representation of chimeric products found with
3′RACE analysis. The white block indicates the scale. In blue, NPRL3 intronic part; in green, NPRL3 exonic part; in red, HBA1 exonic part.
(b) UCSC Genome Browser representation of 5′ ends of the chimeric transcripts on NPRL3 gene. (c) UCSC Genome Browser representation
of 3′ ends of the chimeric transcripts on HBA1 gene. NPRL3, nitrogen permease regulator like protein 3; PCR, polymerase chain reaction;
RACE, rapid amplification of cDNA ends
F IGURE 4 Validation of TAGNPRL3 transcript. (a) UCSC Genome Browser representation of the FW primer (double mapping on the
minisatellite sequence) and the REV primer used for TAGNPRL3 validation. (b) TAGNPRL3 RT‐PCR performed on first‐strand cDNA prepared
from total RNA from PD2, PD13, and HC14 whole blood. PCR products were analysed on a 1% agarose gel with EtBr staining. The main
2,000 bp product corresponds to TAGNPRL3 and its expression is barely detectable in HC14 individual (16/16, low‐tag expressing) whereas is
high in PD2 and PD13 (both 16/13, high‐tag expressing). (c) NPRL3 RT‐PCR performed on the same samples (PD2, PD13, and HC14). PCR
products were analysed on a 1% agarose gel with EtBr staining. The 200 bp product corresponds to NPRL3 and its expression is comparable
among the three individuals. cDNA, complementary DNA; NPRL3, nitrogen permease regulator like protein 3
BERTUZZI ET AL. | 815
fragments contained two repeats variants of the same 29mer unit:
the larger one consists of 16 repeats while the shorter amplicon
consists of 13 repeats. In details, six PD patients (30%) and one
HC individual (5%) (sample HC15) were 16/13 heterozygous.
Interestingly, we noted that the individuals with high‐tag counts,
and therefore highly expressing TAGNPRL3 mRNA, were 16/13
heterozygous.
On the basis of their genotypes we selected 18 RNA samples
among those used for the CAGE analysis: six 16/13 (PD samples) and
12 16/16 (six PD and six HC). We then carried out Real‐Time
TaqMan RT‐PCR with the assays for TAGNPRL3 and NPRL3 mRNAs.
We took advantage of PGK1 as invariant gene for normalization.
TAGNPRL3 high expression was strongly correlated with the 16/13
genotype while it was low in homozygous 16/16 individuals
(Figure 5a). On the other hand, NPRL3 expression levels were quite
variable among different samples but showed no correlation with
genotype (Figure 5b). The expression of both transcripts was not
correlated with PD.
We then assembled an independent set of samples (see Section 2
for details) composed of eight 16/13 and 12 16/16 subjects (details in
Table 2) and performed a Real‐Time TaqMan RT‐PCR in the same
conditions as above (TAGNPRL3, NPRL3, and PGK1 for normalization).
While high TAGNPRL3 expression was linked to the 16/13
minisatellite genotype (Figure 5c) in a statistically significant
manner, NPRL3 expression did not correlate with the genotype
(Figure 5d). Again, no correlation was found between mRNA levels
and PD.
In summary, TAGNPRL3 is a new NPRL3 isoform with a TSS within
a minisatellite region in its third intron. This minisatellite presents
two variants with 16‐ and 13‐repeats. The 13‐repeats allele is
associated to high expression of TAGNPRL3 mRNA.
3.4 | Genomic analysis of VNTR locus
We then carried out an analysis of the VNTR locus for genomic
features and expression data interrogating large consortium data-
sets. The VNTR overlaps two eQTLs identified in the version 6 of the
GTEx (GTEx Consortium, 2013) data analysis. These are associated
to the rs17146023 SNP and result to impact the expression of the
NPRL3 gene in the lung and of RNA polymerase III subunit K
(POLR3K) in the cerebellum. The VNTR also overlaps a DNAse I
hypersensitivity cluster identified within the ENCODE (ENCODE
Project Consortium, 2012) version 3 analysis. Out of 125 cell types,
the DNAse I hypersensitivity site from this VNTR has been identified
only in the T helper 1 (Th1) cell lineage.
To look for potential regulatory networks, we carried out a
binding site analysis using Jaspar (Khan et al., 2018) and identified
myeloid zinc finger 1 (MZF1; Morris, Hromas, & Rauscher, 1994) as
the transcription factor with the highest probability of binding the
VNTR (Figure 6). MZF1 is a zinc finger protein with an established
role in hemopoiesis. In agreement with a potential overlap with an
enhancer region, the VNTR also overlaps a peak of H3K27
F IGURE 5 TAGNPRL3 upregulation in blood is associated to
16/13 minisatellite genotype. Real‐Time TaqMan PCR
normalized with PGK1 assay. Fold change is indicated on the y
axis. 16/16 are indicated in blue/dark and 16/13 in green/light.
(a) TAGNPRL3 assay on selected CAGE samples reveals that its
high expression is linked to 16/13 minisatellite genotype. (b)
NPRL3 assay on selected CAGE samples. Canonical NPRL3
isoform expression is variable among individuals but it is
independent from minisatellite genotype. (c) TAGNPRL3 assay on
an independent sample set (PD and HC, 16/13 and 16/16, see
Table 2) confirmed that all 16/13 individuals (both PD and HC)
express high levels of TAGNPRL3. (d) NPRL3 assay on an
independent sample set (PD and HC, 16/13 and 16/16, see
Table 2). NPRL3 expression is independent from minisatellite
genotype. Data presented as min to max with median. *p < .05;
****p < .0001. CAGE, cap analysis of gene expression; HC, healthy
control; NPRL3, nitrogen permease regulator like protein 3; PCR,
polymerase chain reaction; PD, Parkinson’s disease
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acetylation and falls few hundred nucleotides downstream of a peak
of conservation in 100 vertebrate species.
Notably, a long noncoding RNA is transcribed in antisense
to the NPRL3 gene starting at about 1,500 nucleotides down-
stream the VNTR. It results expressed at very low levels (from
0.04 to 0.45 median transcript per million) in all the tissues
sampled in the GTEx Project, with its higher expression in cervix
and cerebellum.
3.5 | 13‐repeat variant prevalence
We then analysed the prevalence of the 13‐repeats variant. To this
purpose we took advantage of a validation set of PD and HC samples
(see Section 2 for details) and we carried out a PCR‐based genotype
assay. Among a total of 1,124 subjects (both PD patients and HC),
212 were 16/13 (18.86%); 11 subjects were 13/13 (0.98%), and 901
subjects were 16/16 (80.16%). The allelic frequency of the 13‐
repeats was 10.41%. This analysis showed that the 13‐repeat variant
is not linked to PD.
The VNTR sequence in the NPLR3 gene has been included into
the dbVAR, the NCBI’s database of human genomic structural
variation, as nstd179.
3.6 | TAGNPRL3 mRNA is expressed in RBC in a 13‐
repeats‐dependent manner
We then assessed the main source of TAGNPRL3 expression
in the blood. To this purpose we took advantage of two 16/16
HC (MB and RC, from our laboratory stock) and two 16/13 HC
(from the Real‐Time TaqMan PCR validation set; C_43_CS
and C_12_CD, see Table 2) individuals. Blood was collected
into EDTA tubes and PBMC; RBCs and plasma were separated.
After RNA extraction, we performed a Real‐Time TaqMan
RT‐PCR with the assays for TAGNPRL3, NPRL3, and PGK1 for
normalization.
NPRL3 and TAGNPRL3 expression was quite exclusive of RBC
fraction while TAGNPRL3 mRNA was highly expressed in hetero-
zygous individuals. PBMC expressed low levels of NPRL3 while
TAGNPRL3 was undetectable except for individual C_43_CS where
we cannot exclude a minor contamination due to the high level of
TAGNPRL3 mRNA expression (Figure 7). Both NPRL3 and TAGNPRL3
mRNAs were undetectable in plasma (data not shown).
3.7 | TAGNPRL3 protein is highly expressed in RBC
of 16/13 individuals
NPRL3 gene has five annotated different alternative splicing
transcripts. NPRL3 isoform 1 (NM_001077350) encodes for a protein
of 64 kDa. Isoforms 2–5 are predicted to translate a shorter NPRL3
protein, starting from an alternative AUG, but they were undetect-
able in several cell types (Lunardi et al., 2009). The coding sequence
of TAGNPRL3 corresponds to the coding sequence of NPRL3 isoform
3 (NM_001243247) but with different UTRs. Respect to isoform 1,
TAGNPRL3 and NPRL3 isoform 3 share a N‐terminal truncated
(Δ1–78 amino acids) NPRL3 protein.
After confirming with an siRNA experiment that the anti‐NPRL3
antibody (1:500; Cat #ab121346; Abcam) specifically detects endo-
genous NPRL3 in SH‐SY5Y cells (Figure S2A), we cloned the full‐length
cDNA sequence of TAGNPRL3 into the pcDNA3.1‐expression vector
and transiently transfected it into HEK 293T cells. As shown in Figure
S2B, TAGNPRL3 was detected as a 60 kDa migrating band while the
NPRL3 isoform 1 gave rise to a 64 kDa protein. Both proteins
migrated at an apparent molecular weight higher than their conceptual
translation (55 kDa for TAGNPRL3 and 60 kDa for NPRL3 isoform 1).
TABLE 2 List of real‐time TaqMan polymerase chain reaction
blood samples and their minisatellite genotype
Experiment Minisatellite genotype Sample name
Validation 16/16 2C
5C
7C
8C
10C
14C
16/13 15C
16/16 1PD
6PD
8PD
9PD
10PD
19PD
16/13 2PD
4PD
7PD
11PD
13PD
18PD
Independent 16/16 PD_C2616
PD_M2371
PD_Z0411
PD_S1613
PD_T0770
PD_C2766
16/13 PD_025
PD_022
PD_Z0397
PD_G1593
16/16 C_49AB
C_51PR
C_52FC
C_54MK
C_47IC
C_48MK
16/13 C_12CD
C_28CD
C_43SB
C_43CS
Note: The two samples in bold have been used for the fractionation
experiment.
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Immunofluorescence analysis showed that both isoforms present a
similar nucleocytoplasmic distribution (Figure S2C). We then assessed
the main source of TAGNPRL3 protein expression in the blood in vivo
and whether TAGNPRL3 protein levels were dependent on the
presence of the 13‐repeats variant. To this purpose we carried out
whole blood fractionation of sample MB, a 16/16 HC, collecting PBMC
and RBC fractions. After preparing protein lysates, by western blot
analysis we detected a band of about 60 kDa in whole blood and RBCs,
as expected from RNA expression analysis. Endogenous bands were of
similar size of the one detected ectopically expressing TAGNPRL3
cDNA in HEK 293T cells (Figure 8a). We then compared the
expression in RBC of MB with two 16/13 HC individuals (C_43_CS
and C_12_CD), as previously carried out for TAGNPRL3 mRNA levels.
As expected, TAGNPRL3 protein was highly expressed in the two 16/
13 HC compared with the 16/16 individual proving that high mRNA
levels lead to higher protein expression in RBC (Figure 8b). Although
the protein band in this experiment does not correspond exactly in
migration size to the overexpressed protein in HEK 293T cells, we
hypothesize this may be due to the different lysate preparations and
total protein amount loaded on the gel. Furthermore, we cannot
exclude the presence of cell‐type specific posttranslational
modifications.
3.8 | TAGNPRL3 protein maintains properties
of NPRL3 isoform 1
NPRL3 isoform 1 dimerizes with its partner NPRL2 and, together
with DEPCDC5, they form a protein complex called GATOR1 in
mammals, which in turns is involved in many cellular processes such
as stimulation of protein synthesis, growth, metabolism, and the
inhibition of autophagy (Bar‐Peled et al., 2013). Furthermore, NPRL3
is also able to inhibit cell proliferation. It is therefore important to
carry out a preliminary assessment of the ability of the TAGNPRL3
protein to maintain some of the biological function of NPRL3
isoform 1.
To assess if TAGNPRL3‐encoded protein could interact with
NPRL2, a coimmunoprecipitation assay has been set up by
cotransfecting HEK cells with NPRL2_MYC and TAGNPRL3. As
control, we used NPRL3 isoform 1 and NPRL3 isoform 2: the former
is the canonical NPRL3 isoform involved in GATOR1 complex, the
latter is a N‐terminal truncated (Δ1–179 amino acids) protein‐coding
isoform. According to Levine et al. (2013), NPRL3 isoform 2 should
not coimmunoprecipitate because it lacks the N‐terminal longin
domain that should dimerize with the N‐terminal longin domain of
NPRL2. As shown in Figure 9a, NPRL2 interacted with all the three
different NPRL3 isoforms. This result suggests that there could be at
least one additional domain involved in dimerization. To investigate
whether TAGNPRL3‐encoded protein inhibits proliferation as NPRL3
(Lunardi et al., 2009), we transfected plasmids expressing TAGNPRL3
or GFP and assayed cells proliferation after 48 hr with BrdU staining.
By immunofluorescence with anti‐BrdU antibody, we found that
TAGNPRL3‐transfected cells showed a significant decrease in the rate
of proliferation compared with controls: an average of 40% of GFP‐
positive cells were growing in control experiment while only about
20% of TAGNPRL3‐overexpressing cells incorporated BrdU. We thus
proved that TAGNPRL3 retains NPRL3 isoform ability to inhibit cell
proliferation (Figure 9b).
F IGURE 6 Analysis of genomic features of VNTR locus. Image modified from the UCSC genome browser (Casper et al., 2018) describing the
genomic context of the VNTR (in red). The region represents a portion of the intron of the NPRL3 gene containing the VNTR. The genomic
features overlapped by the VNTR are highlighted in the light orange box. The antisense long noncoding RNA transcribed within the intron is the
green transcript at the end of the figure. NPRL3, nitrogen permease regulator like protein 3; VNTR, variable number of tandem repeat
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4 | DISCUSSION
The FANTOM projects have profoundly changed the view of the
mammalian transcriptome. First, in conjunction with the isolation of a
very large collection of full length cDNAs, many additional types of
RNAs were identified leading to the discovery of long noncoding
RNAs. By the use of CAGE in combination with a paired‐end tag
sequencing method (Wei et al., 2004), it was unveiled that the
genome is pervasively transcribed—with more than 63% of the
genome producing transcripts (Carninci et al., 2005), and more than
73% of the genes showing some form of antisense transcription
(Katayama et al., 2005). A first comprehensive promoter map both
for human and mouse (Carninci et al., 2006) was then assembled
leading to the discovery of different classes of promoter architec-
tures (Carninci et al., 2006; Lenhard, Sandelin, & Carninci, 2012).
Furthermore, REs were shown to be frequently transcribed in a cell‐
type specific and regulated manner (Faulkner et al., 2009). This
provided evidence that REs contained promoters driving the
transcription of coding and noncoding RNAs in various tissues,
especially in embryonic stages where long interspersed nuclear
element and long terminal repeat elements are particularly active.
Here we show that CAGE tags identify a TSS host by minisatellite
sequences and that its expression is influenced by genomic VNTRs.
Since their first description in the 80s, minisatellites have been
intensely studied for their high degree of polymorphism and
effects on the expression of the adjacent gene. While most of them
are quite stable, selected loci, called hypermutable minisatellites,
show hypervariability leading to the establishment of human DNA
fingerprinting assays (Denoeud, Vergnaud, & Benson, 2003).
Minisatellites polymorphisms in the coding region of a gene are
the best candidates for functional effects. The most studied example
is the minisatellite present in the third exon of the dopamine
receptor D4 (DRD4) gene that has been associated with attention
deficit hyperactive disorder, response to clozapine in schizophrenia
treatment (Shaikh et al., 1993) and other neurological disorders. The
48 bp minisatellite ranges from 2 to 11 repeats and, once translated,
F IGURE 7 Red blood cells are the main source of TAGNPRL3
expression in blood and the 16/13 minisatellite genotype induces
TAGNPRL3 transcript. Real‐Time TaqMan PCR on blood fractions of
four HC: two heterozygous (C_43_CS and C_12_CD) and two
homozygous (MB and RC). Whole blood samples have been
fractionated with Histopaque®‐1077 reagent (Sigma‐Aldrich) and
total RNAs have been extracted with TRIzol reagent (Invitrogen).
After cDNA preparation, Real‐Time TaqMan assays have been
performed. (a) NPRL3 assay shows that its expression is variable
among the four individuals and ubiquitous in the cell fractions,
although prevalent in RBC. (b) TAGNPRL3 assay shows that its
expression seems to be exclusive of RBC (except from C_43_CS
PBMC) and it is highly induced in the RBC of heterozygous
individuals. Data presented as mean ± SEM of three technical
replicates. NPRL3, nitrogen permease regulator like protein 3;
PBMC, peripheral blood mononuclear cell; RBC, red blood cell
F IGURE 8 TAGNPRL3 protein expression analysis. (a) Western
blot analysis with anti‐NPRL3 and anti‐β actin antibodies of MB, a
16/16 HC individual. WB, PBMC, and RBC are compared with cell
lysates of HEK 293T cells upon TAGNPRL3 and NPRL3 isoform 1
transfection. As expected from analysis of TAGNPRL3mRNA levels in
the same individual, TAGNPRL3 protein is expressed mainly in RBC.
Endogenous bands were of similar size of the one detected
ectopically expressing TAGNPRL3 cDNA. (b) Western blot analysis
with anti‐NPRL3 and anti‐β ACTIN antibodies of RBC of MB and two
16/13 HC individuals (C_43_CS and C_12_CD). TAGNPRL3 protein
was highly expressed in the two 16/13 HC compared with the 16/16
individual proving that high mRNA levels lead to higher protein
expression in RBC. mRNA, messenger RNA; NPRL3, nitrogen
permease regulator like protein 3; PBMC, peripheral blood
mononuclear cell; RBC, red blood cell; WB, whole blood
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each TR adds 16 amino acids to the third cytoplasmic loop of the
protein (Chio et al., 1994; Van Tol et al., 1992). Albeit the function of
the receptor is only partially influenced by the number of repeats
and only in certain conditions, different DRD4 variants display
differential sensitivity to dopamine chaperone effect in the cell
(Van Craenenbroeck, De Bosscher, Vanden Berghe, Vanhoenacker, &
Haegeman, 2005).
Minisatellite polymorphisms are also found in promoters where
they may influence gene expression levels. As representative
examples, the 20–23 bp of the 5HTT promoter are repeated 14 or
16 times and its short variant reduces transcriptional efficiency. It is
associated to anxiety‐related traits (Lesch et al., 1996), increased risk
of depression (Lotrich & Pollock, 2004), and reduced gray matter
volume and connectivity in limbic regions (Pezawas et al., 2005).
MAOA gene has a 30 bp repeat sequence in the promoter region
which variants are associated to its mRNA levels. These may
influence bipolar disorder, impulsivity, and antisocial behaviour
(Brookes, 2013). Finally, minisatellite polymorphisms can be present
in intronic and UTRs of genes influencing RNA splicing, localization,
stability, and translational efficiency. A 3′‐UTR minisatellite of 40 bp
repeated 7–11 times influences the expression of the dopamine
transporter gene (DAT1/SLC6A3), which in turn affect dopamine
re‐uptake processes and behaviour (Brookes, 2013).
Nevertheless, since they are not represented in CGH and SNPs
arrays, the genome‐wide identification of minisatellite polymorph-
isms present in noncoding regions and acting as eQTL remains
elusive.
The NPRL3‐associated VNTR is a 29 nt long minisatellite with two
variants of 16 and 13 repeats. By mapping CAGE tags and 5′RACE
sequencing data, we found that TSS of TAGNPRL3 mRNA localizes in
the 11th repeat, the one that exclusively presents the tag sequence
despite the high homology between repeats. Transcription starts
from a relatively uncommon core promoter sequence called TCT
motif (YC+1TYTYY), which has been found to be specific for genes of
ribosomal and translation‐related proteins (Parry et al., 2010). This is
intriguing since NPRL3 ablation in mice causes the perturbation of
protein synthesis (Kowalczyk et al., 2012a).
While our initial observation suggested that high levels of
TAGNPRL3 mRNA expression in the blood can be associated to PD
in a portion of cases, the analysis of a larger number of individuals
F IGURE 9 Coimmunoprecipitation of NPRL2 with NPRL3 isoforms. (a) Western blot showing the coimmunoprecipitation assay in HEK 293T
cells transiently transfected with NPRL2 and one of the three NPRL3 isoforms. After 24 hr from transfection, cell lysates have been incubated
with Myc antibody that recognize the C‐terminal tag of NPRL2. Protein G Sepharose beads have been used to precipitate the protein complexes
bound by Myc antibody that have been tested for NPRL3 isoforms presence by western blot. NPRL2 coimmunoprecipitates with all the three
NPRL3 isoforms. (b) TAGNPRL3 retains the ability of the full‐length protein to inhibit proliferation, since it inhibits BrdU incorporation. A vector
expressing GFP was transfected as a control. The y axis indicates the % of BrdU positive cells in the transfected population. N = 4. BrdU,
bromodeoxyuridine; GFP, green fluorescent protein; NPRL3, nitrogen permease regulator like protein 3
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proved that high TAGNPRL3 were occurring in 16/13 and not in
16/16 minisatellite genotypes, irrespective of the pathology. This
may suggest that a selective group of individuals within the local
population shows a higher allelic frequency of the 13‐repeats variant
independently of PD. Future population studies may address this
important point.
The molecular basis of TAGNPRL3 differential expression and its
dependency on repeat number remains unclear as well as whether
the 13‐repeat variant influences the level of TAGNPRL3 expression in
other tissues including the brain. As expected, minisatellite variants
do not influence NPRL3 canonical isoform 1 mRNA expression. The
VNTR locus overlaps two eQTLs that are associated to a SNP
modulating the expression of the NPRL3 gene in the lung. It also
overlaps a DNAse I hypersensitivity cluster that has been previously
identified in the Th1 cell lineage. In agreement with a potential
overlap with an enhancer region, the VNTR also overlaps a peak of
H3K27 acetylation. By transcription factor binding site analysis
we identified MZF1 as the transcription factor with the highest
probability of binding the VNTR. Since MZF1 is involved in
hemopoiesis, future work will investigate a potential causal relation-
ship between the expression of this zinc finger protein and
transcription at this locus. Since a long noncoding RNA is transcribed
in antisense to the NPRL3 gene starting at about 1,500 nucleotides
downstream the VNTR, it will be also worth investigating whether its
expression is dependent on the VNTR alleles.
TAGNPRL3 mRNAs expression occurs in RBCs of 16/13 indivi-
duals and is increased in RBCs of 16/13 genotypes. This pattern
seems mirrored at the protein levels since we found that a band
migrating at the same apparent size of transfected TAGNPRL3 was
present in RBC of the very same 16/16 HC. Furthermore, when
comparing RBC of this individual with those of two 16/13 we
detected a much higher expression in heterozygotes. While in our
experimental conditions the migration of the TAGNPRL3 protein
from RBC lysates of 16/13 individuals does not perfectly mimic the
one from overexpressing TAGNPRL3 cDNA in HEK 293T cells, it is
very likely that they are indeed the same protein and this difference
may be due to different lysate preparations (RBC vs. a cultured
cell line) and total protein amounts loaded on gel (much less in the
case of overexpressing HEK 293T cells). Importantly, we cannot
exclude the presence of cell‐type specific posttranslational
modifications since TAGNPRL3 presents consensus sequences for
ubiquitination and phosphorylation.
Interestingly, a SNP in NPRL3 first intron (rs7203560) has been
found correlated to haemolysis in sickle cell anemia (Milton et al.,
2013). Furthermore, the minisatellite maps only 3 kb away of
MCS‐R3, one of the major α‐globin enhancer (Higgs, 2013). Future
work will assess whether minisatellite alleles may influence hemo-
globin expression.
A central question concerns the biological significance of
TAGNPRL3. NPRL3 dimerizes with its homologous NPRL2 and was
initially identified as mediating an amino acid starvation signal to
TORC1 in yeast. Together with DEPDC5, they form the GATOR1
protein complex, an evolutionary conserved inhibitor of mTORC1
activity (Wei, Reveal, Cai, & Lilly, 2016). Recently, NPRL3 gene
mutations have been found in FCD and in familial focal epilepsy (Sim
et al., 2015) where the loss of NPRL3 function led to mTOR
dysregulation. In eukaryotes, TOR is the major sensor of nutrients,
energy, and stress. Alterations in its pathway have been correlated
with diseases and conditions where growth and homeostasis are
compromised like cancer, metabolic diseases, and aging (Bjedov et al.,
2010; Hansen et al., 2008; Johnson, Rabinovitch, & Kaeberlein, 2013;
Ravikumar et al., 2004). It is therefore tempting to speculate that
TAGNPRL3 expression levels may influence mTOR activity and
regulate metabolic homeostasis and cellular response to stress. In the
blood, imbalances in mTORC1 function lead to different types of
anemias with changes in RBC size, number, and hemoglobin content
while its pharmacological activation can ameliorate some types of
hereditary anemias (Bayeva et al., 2012; Jaako et al., 2012; Knight,
Schmidt, Birsoy, Tan, & Friedman, 2014; La, Yang, & Dennery, 2013;
Ohyashiki et al., 2009; Payne et al., 2012). Interestingly, NPRL2
absence in mice severely compromises hematopoiesis (Dutchak
et al., 2015).
The functional effects of TAGNPRL3 should be discussed in terms
of isoform protein structure and level of expression. TAGNPRL3
encodes for a nucleocytoplasmic protein lacking the first 78 amino
acids at the N‐terminal of isoform 1. We experimentally showed that
TAGNPRL3 maintains two features of the full‐length protein. First,
TAGNPRL3 is able to bind its partner NPRL2 and therefore
potentially be part of the GATOR1 complex. Interestingly, our data
shows that LD at the N‐terminal (Levine et al., 2013) is not required
for this interaction since NPRL3 isoform 2, lacking this domain,
maintains its ability to dimerize with NPRL2. Furthermore, by
performing BrdU assays, we demonstrated that TAGNPRL3 is able
to inhibit proliferation. Since this function seems to be dependent on
the binding of the NPRL3 isoform 1 to all p53‐family proteins
(Lunardi et al., 2009), further experiments should assess whether
TAGNPRL3 is able to preserve these protein interactions.
A crucial open question concerns which fraction of the increased
quantity of TAGNPRL3, driven by the 13‐repeat variant, is included
in the GATOR1 complex and whether an increased TAGNPRL3
expression influences mTORC1 activity. While in our cohort the 13‐
repeat variant presents an allelic frequency of 10.41%, genetic
analysis of TAGNPRL3 VNTRs should be carried out for all those
pathological contexts dependent on mTORC1 activity. It will be also
interesting to address whether the lack of the N‐terminal portion can
influence selected NPRL3 protein interactions or biochemical
activities as well as gives rise to a dominant negative isoform.
In summary, this study provides a new example of a VNTR that is
both a TSS and an eQTL of an important gene crucial for mTORC1
regulation and in a genomic location enriched in regulatory elements
for α globins.
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